Titration of signalling output: insights into clinical combinations of MEK and AKT inhibitors (English)
- New search for: Stewart, A.
- New search for: Thavasu, P.
- New search for: de Bono, J. S.
- New search for: Banerji, U.
- New search for: Stewart, A.
- New search for: Thavasu, P.
- New search for: de Bono, J. S.
- New search for: Banerji, U.
In:
ANNALS OF ONCOLOGY
;
26
, 7
;
1504-1510
;
2015
-
ISSN:
- Article (Journal) / Print
-
Title:Titration of signalling output: insights into clinical combinations of MEK and AKT inhibitors
-
Contributors:Stewart, A. ( author ) / Thavasu, P. ( author ) / de Bono, J. S. ( author ) / Banerji, U. ( author )
-
Published in:ANNALS OF ONCOLOGY ; 26, 7 ; 1504-1510
-
Publisher:
- New search for: OXFORD UNIVERSITY PRESS
-
Publication date:2015-01-01
-
Size:7 pages
-
ISSN:
-
Type of media:Article (Journal)
-
Type of material:Print
-
Language:English
- New search for: 616.992
- Further information on Dewey Decimal Classification
-
Classification:
DDC: 616.992 -
Source:
© Metadata Copyright the British Library Board and other contributors. All rights reserved.
Table of contents – Volume 26, Issue 7
The tables of contents are generated automatically and are based on the data records of the individual contributions available in the index of the TIB portal. The display of the Tables of Contents may therefore be incomplete.
- 1275
-
De-escalation attempts for adjuvant trastuzumab: longer beats shorterCurigliano, G. / Goldhirsch, A. et al. | 2015
- 1277
-
Pharmacokinetic and pharmacodynamic end points with anti-VEGFR: the more it hurts, the more it works?Mir, O. / Dumont, S. / Armand, J. P. et al. | 2015
- 1279
-
‘Industry corner: perspectives and controversies’: a new series in Annals of OncologyDhingra, K. et al. | 2015
- 1280
-
Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaborationBossuyt, V. / Provenzano, E. / Symmans, W. F. / Boughey, J. C. / Coles, C. / Curigliano, G. / Dixon, J. M. / Esserman, L. J. / Fastner, G. / Kuehn, T. et al. | 2015
- 1291
-
Genetics of breast cancer: a topic in evolutionShiovitz, S. / Korde, L. A. et al. | 2015
- 1300
-
Alternate sunitinib schedules in patients with metastatic renal cell carcinomaKalra, S. / Rini, B. I. / Jonasch, E. et al. | 2015
- 1305
-
First-line treatment and outcome of elderly patients with primary central nervous system lymphoma (PCNSL)—a systematic review and individual patient data meta-analysisKasenda, B. / Ferreri, A. J. / Marturano, E. / Forst, D. / Bromberg, J. / Ghesquieres, H. / Ferlay, C. / Blay, J. Y. / Hoang-Xuan, K. / Pulczynski, E. J. et al. | 2015
- 1314
-
The potential for epigenetic analysis of paediatric CNS tumours to improve diagnosis, treatment and prognosisSexton-Oates, A. / MacGregor, D. / Dodgshun, A. / Saffery, R. et al. | 2015
- 1325
-
Consideration of comorbidity in treatment decision making in multidisciplinary cancer team meetings: a systematic reviewStairmand, J. / Signal, L. / Sarfati, D. / Jackson, C. / Batten, L. / Holdaway, M. / Cunningham, C. et al. | 2015
- 1333
-
Six versus 12 months of adjuvant trastuzumab in combination with dose-dense chemotherapy for women with HER2-positive breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG)Mavroudis, D. / Saloustros, E. / Malamos, N. / Kakolyris, S. / Boukovinas, I. / Papakotoulas, P. / Kentepozidis, N. / Ziras, N. / Georgoulias, V. et al. | 2015
- 1340
-
Extreme chromosomal instability forecasts improved outcome in ER-negative breast cancer: a prospective validation cohort study from the TACT trialJamal-Hanjani, M. / A'Hern, R. / Birkbak, N. J. / Gorman, P. / Grönroos, E. / Ngang, S. / Nicola, P. / Rahman, L. / Thanopoulou, E. / Kelly, G. et al. | 2015
- 1346
-
Inhibition of the phosphoinositide 3-kinase pathway for the treatment of patients with metastatic metaplastic breast cancerMoulder, S. / Helgason, T. / Janku, F. / Wheler, J. / Moroney, J. / Booser, D. / Albarracin, C. / Morrow, P. K. / Atkins, J. / Koenig, K. et al. | 2015
- 1353
-
ELYPSE-7: a randomized placebo-controlled phase IIa trial with CYT107 exploring the restoration of CD4+ lymphocyte count in lymphopenic metastatic breast cancer patientsTrédan, O. / Ménétrier-Caux, C. / Ray-Coquard, I. / Garin, G. / Cropet, C. / Verronèse, E. / Bachelot, T. / Rebattu, P. / Heudel, P. E. / Cassier, P. et al. | 2015
- 1363
-
Profiling cancer gene mutations in longitudinal epithelial ovarian cancer biopsies by targeted next-generation sequencing: a retrospective studyBeltrame, L. / Di Marino, M. / Fruscio, R. / Calura, E. / Chapman, B. / Clivio, L. / Sina, F. / Mele, C. / Iatropoulos, P. / Grassi, T. et al. | 2015
- 1372
-
Axitinib dose titration: analyses of exposure, blood pressure and clinical response from a randomized phase II study in metastatic renal cell carcinomaRini, B. I. / Melichar, B. / Fishman, M. N. / Oya, M. / Pithavala, Y. K. / Chen, Y. / Bair, A. H. / Grünwald, V. et al. | 2015
- 1378
-
RECORD-2: phase II randomized study of everolimus and bevacizumab versus interferon α-2a and bevacizumab as first-line therapy in patients with metastatic renal cell carcinomaRavaud, A. / Barrios, C. H. / Alekseev, B. / Tay, M. H. / Agarwala, S. S. / Yalcin, S. / Lin, C. C. / Roman, L. / Shkolnik, M. / Anak, O. et al. | 2015
- 1385
-
Clinical usefulness of PI3K/Akt/mTOR genotyping in companion with other clinical variables in metastatic renal cell carcinoma patients treated with everolimus in the second and subsequent linesBodnar, L. / Stec, R. / Cierniak, S. / Synowiec, A. / Wcisło, G. / Jesiotr, M. / Koktysz, R. / Kozłowski, W. / Szczylik, C. et al. | 2015
- 1390
-
High PSA anxiety and low health literacy skills: drivers of early use of salvage ADT among men with biochemically recurrent prostate cancer after radiotherapy?Mahal, B. A. / Chen, M. H. / Bennett, C. L. / Kattan, M. W. / Sartor, O. / Stein, K. / D'Amico, A. V. / Nguyen, P. L. et al. | 2015
- 1396
-
A refined risk stratification scheme for clinical stage 1 NSGCT based on evaluation of both embryonal predominance and lymphovascular invasionLago-Hernandez, C. A. / Feldman, H. / O'Donnell, E. / Mahal, B. A. / Perez, V. / Howard, S. / Rosenthal, M. / Cheng, S. C. / Nguyen, P. L. / Beard, C. et al. | 2015
- 1401
-
A randomized phase III trial of oral S-1 plus cisplatin versus docetaxel plus cisplatin in Japanese patients with advanced non-small-cell lung cancer: TCOG0701 CATS trialKubota, K. / Sakai, H. / Katakami, N. / Nishio, M. / Inoue, A. / Okamoto, H. / Isobe, H. / Kunitoh, H. / Takiguchi, Y. / Kobayashi, K. et al. | 2015
- 1408
-
High level of chromosomal instability in circulating tumor cells of ROS1-rearranged non-small-cell lung cancerPailler, E. / Auger, N. / Lindsay, C. R. / Vielh, P. / Islas-Morris-Hernandez, A. / Borget, I. / Ngo-Camus, M. / Planchard, D. / Soria, J. C. / Besse, B. et al. | 2015
- 1415
-
Biomarker testing and time to treatment decision in patients with advanced nonsmall-cell lung cancerâ€Lim, C. / Tsao, M. S. / Le, L. W. / Shepherd, F. A. / Feld, R. / Burkes, R. L. / Liu, G. / Kamel-Reid, S. / Hwang, D. / Tanguay, J. et al. | 2015
- 1421
-
Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumorsKris, M. G. / Camidge, D. R. / Giaccone, G. / Hida, T. / Li, B. T. / O'Connell, J. / Taylor, I. / Zhang, H. / Arcila, M. E. / Goldberg, Z. et al. | 2015
- 1427
-
FOLFIRI plus bevacizumab as second-line therapy in patients with metastatic colorectal cancer after first-line bevacizumab plus oxaliplatin-based therapy: the randomized phase III EAGLE studyâ€Iwamoto, S. / Takahashi, T. / Tamagawa, H. / Nakamura, M. / Munemoto, Y. / Kato, T. / Hata, T. / Denda, T. / Morita, Y. / Inukai, M. et al. | 2015
- 1434
-
Mito-FLAG with Ara-C as bolus versus continuous infusion in recurrent or refractory AML—long-term results of a prospective randomized intergroup study of the East German Study Group Hematology/Oncology (OSHO) and the Study Alliance Leukemia (SAL)â€Thiel, A. / Schetelig, J. / Pönisch, W. / Schäfer-Eckart, K. / Aulitzky, W. / Peter, N. / Schulze, A. / Maschmeyer, G. / Neugebauer, S. / Herbst, R. et al. | 2015
- 1440
-
Differences in attitudes and beliefs toward end-of-life care between hematologic and solid tumor oncology specialistsHui, D. / Bansal, S. / Park, M. / Reddy, A. / Cortes, J. / Fossella, F. / Bruera, E. et al. | 2015
- 1446
-
Association of proinflammatory cytokines and chemotherapy-associated cognitive impairment in breast cancer patients: a multi-centered, prospective, cohort studyâ€Cheung, Y. T. / Ng, T. / Shwe, M. / Ho, H. K. / Foo, K. M. / Cham, M. T. / Lee, J. A. / Fan, G. / Tan, Y. P. / Yong, W. S. et al. | 2015
- 1452
-
The effect of filgrastim or pegfilgrastim on survival outcomes of patients with cancer receiving myelosuppressive chemotherapyLyman, G. H. / Reiner, M. / Morrow, P. K. / Crawford, J. et al. | 2015
- 1459
-
Doxorubicin plus the IGF-1R antibody cixutumumab in soft tissue sarcoma: a phase I study using the TITE-CRM modelChugh, R. / Griffith, K. A. / Davis, E. J. / Thomas, D. G. / Zavala, J. D. / Metko, G. / Brockstein, B. / Undevia, S. D. / Stadler, W. M. / Schuetze, S. M. et al. | 2015
- 1465
-
Aplidin in patients with advanced dedifferentiated liposarcomas: a French Sarcoma Group Single-Arm Phase II studyToulmonde, M. / Le Cesne, A. / Piperno-Neumann, S. / Penel, N. / Chevreau, C. / Duffaud, F. / Bellera, C. / Italiano, A. et al. | 2015
- 1470
-
Plasma vemurafenib concentrations in advanced BRAFV600mut melanoma patients: impact on tumour response and toleranceâ€Funck-Brentano, E. / Alvarez, J. C. / Longvert, C. / Abe, E. / Beauchet, A. / Funck-Brentano, C. / Saiag, P. et al. | 2015
- 1476
-
Phase II trial of everolimus and erlotinib in patients with platinum-resistant recurrent and/or metastatic head and neck squamous cell carcinomaMassarelli, E. / Lin, H. / Ginsberg, L. E. / Tran, H. T. / Lee, J. J. / Canales, J. R. / Williams, M. D. / Blumenschein, G. R. / Lu, C. / Heymach, J. V. et al. | 2015
- 1481
-
Phase I dose-escalating trial of Escherichia coli purine nucleoside phosphorylase and fludarabine gene therapy for advanced solid tumorsâ€Rosenthal, E. L. / Chung, T. K. / Parker, W. B. / Allan, P. W. / Clemons, L. / Lowman, D. / Hong, J. / Hunt, F. R. / Richman, J. / Conry, R. M. et al. | 2015
- 1488
-
PD-L1 protein expression in breast cancer is rare, enriched in basal-like tumours and associated with infiltrating lymphocytesAli, H. R. / Glont, S. E. / Blows, F. M. / Provenzano, E. / Dawson, S. J. / Liu, B. / Hiller, L. / Dunn, J. / Poole, C. J. / Bowden, S. et al. | 2015
- 1494
-
Benefit to neoadjuvant anti-human epidermal growth factor receptor 2 (HER2)-targeted therapies in HER2-positive primary breast cancer is independent of phosphatase and tensin homolog deleted from chromosome 10 (PTEN) statusNuciforo, P. G. / Aura, C. / Holmes, E. / Prudkin, L. / Jimenez, J. / Martinez, P. / Ameels, H. / de la Peña, L. / Ellis, C. / Eidtmann, H. et al. | 2015
- 1500
-
Variation in transplacental transfer of tyrosine kinase inhibitors in the human perfused cotyledon modelJovelet, C. / Seck, A. / Mir, O. / Simasotchi, C. / Broutin, S. / Goffinet, F. / Bidart, J. M. / Paci, A. / Gil, S. et al. | 2015
- 1504
-
Titration of signalling output: insights into clinical combinations of MEK and AKT inhibitorsStewart, A. / Thavasu, P. / de Bono, J. S. / Banerji, U. et al. | 2015
- 1511
-
Sunitinib 2 weeks on, 1 off: strengths and weaknessesIacovelli, R. / Verri, E. / Cossu Rocca, M. / Aurilio, G. / Cullurà , D. / Nolé, F. et al. | 2015
- 1511
-
Duration of endocrine therapy and its impact on the results of adjuvant trials in premenopausal breast cancer patientsFouad, T. M. / de Azambuja, E. / Azim, H. A. et al. | 2015
- 1512
-
Alternative sunitinib schedules in metastatic renal cell carcinoma and the RAINBOW studyBracarda, S. et al. | 2015
- 1513
-
Agenda science: turning nothing into something: a response to the editorial by Oldenburg et al. and its featured article by Vidal et al.Kollmannsberger, C. / Nichols, C. et al. | 2015
- 1514
-
ALK FISH rearranged and amplified tumor with negative immunohistochemistry: a rare and challenging case concerning ALK status screening in lung cancerUguen, A. / Talagas, M. / Andrieu-Key, S. / Costa, S. / Quintin-Roué, I. / De Braekeleer, M. / Marcorelles, P. et al. | 2015
- 1515
-
Different effects of the BIM deletion polymorphism on treatment of solid tumors by the tyrosine kinase inhibitors (TKI) pazopanib, sunitinib, and lapatinibSpraggs, C. F. / Parham, L. R. / Song, K. / Briley, L. P. / Johnson, T. / Russo, M. / Tada, H. / du Bois, A. / Xu, C. F. et al. | 2015
- 1518
-
Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter studyDieci, M. V. / Criscitiello, C. / Goubar, A. / Viale, G. / Conte, P. / Guarneri, V. / Ficarra, G. / Mathieu, M. C. / Delaloge, S. / Curigliano, G. et al. | 2015